Alerts will be sent to your verified email
Verify Email
VALIANTLAB
|
Valiant Laboratories
|
Trident Lifeline
|
Bafna Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
9.66 % | 31.52 % | 0.0 |
|
5yr average Equity Multiplier
|
1.76 | 2.03 | 3.77 |
|
5yr Average Asset Turnover Ratio
|
0.81 | 0.82 | 0.42 |
|
5yr Avg Net Profit Margin
|
2.4 % | 16.21 % | -36.55 % |
|
Price to Book
|
0.9 | 3.62 | 3.49 |
|
P/E
|
0.0 | 24.91 | 30.62 |
|
5yr Avg Cash Conversion Cycle
|
75.62 Days | 61.09 Days | 0.18 Days |
|
Inventory Days
|
18.84 Days | 72.84 Days | 87.65 Days |
|
Days Receivable
|
161.25 Days | 86.3 Days | 132.64 Days |
|
Days Payable
|
82.33 Days | 122.66 Days | 210.48 Days |
|
5yr Average Interest Coverage Ratio
|
44.93 | 14.53 | -5.68 |
|
5yr Avg ROCE
|
7.68 % | 26.3 % | -11.61 % |
|
5yr Avg Operating Profit Margin
|
0.79 % | 16.98 % | -21.98 % |
|
5 yr average Debt to Equity
|
0.48 | 0.47 | 1.41 |
|
5yr CAGR Net Profit
|
n/a | 24.36 % | 12.0 % |
|
5yr Average Return on Assets
|
4.39 % | 13.79 % | -16.11 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
74.94 % | 64.11 % | 75.0 % |
|
Share Pledged by Promoters
|
0.0 | 6.77 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -5.74 % | -15.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Valiant Laboratories
|
Trident Lifeline
|
Bafna Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|